Skip to content
Markets News
Stocks1 min read

FDA Requires New Eye-Risk Warnings on GLP-1 Drugs

Makkler Newsroom
November 10, 2026 · Based on reporting by CNBC, Ekonomim

The agency is calling for labels to flag a possible link to a rare eye condition, though a causal relationship has not been established.

Key takeaways

  • The FDA is requiring all GLP-1 drug makers to add a warning about possible NAION risk.
  • An analysis of 126 trials found more NAION cases among GLP-1 users than among comparison patients.

The U.S. Food and Drug Administration is requiring makers of all GLP-1 drugs to add warnings about a possible increased risk of NAION, a rare eye condition that can cause sudden vision loss.

The FDA said cases had been reported for all marketed GLP-1 products. A causal relationship has not been established. The agency reviewed clinical trial data, observational studies and safety reports.

An analysis of 126 trials involving more than 134,000 patients found 6.4 NAION cases per 100,000 patient-years among GLP-1 users, compared with 3.8 among people receiving other treatments or placebos.

Eli Lilly said the FDA notice covers the drug class and is not based on a finding specific to its products. Novo Nordisk said current data do not establish cause and effect, and that it remains confident in its medicines’ benefit-risk profile.

Topics

Comments (0)

Log in to join the discussion.Log in

No comments yet - be the first to weigh in.